USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ProLynx LLC
Address:
211 Belgrave Ave
San Francisco, CA 94117-3851
Phone:
N/A
URL:
N/A
EIN:
270333993
DUNS:
831183954
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $443,608.00 3

Award List:

Releasable site-specific attachment of macromolecules to therapeutic peptides

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$143,958.00
Agency:
HHS
Principal Investigator:
Gary W. Ashley
Abstract:
DESCRIPTION (provided by applicant): Many potent and specific peptides suffer problems of short or sub-optimal duration. A possible solution to such problems involves conjugation to macromolecules such as polyethylene glycol (PEG) that are slowly eliminate d from the body, and thus prolongs the… More

Releasable attachment of drugs to PEGylated dendrimers

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$149,650.00
Agency:
HHS
Principal Investigator:
Daniel V. Santi
Abstract:
DESCRIPTION (provided by applicant): We are developing a platform technology that allows predictable, controlled release of drugs from macromolecule-drug conjugates. In one current format, PEG of sufficient size to have prolonged blood circulation times is attached to the drug by linkers designed… More

SBIR Phase I: Controlled Drug Release from and Degradation of PEG-Hydrogels

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$150,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research Phase I project seeks to develop novel hydrogel drug-delivery systems. We have developed linkers for drug conjugation to circulating macromolecules that release the native drug by beta-eliminative cleavage at predictable rates with half-lives spanning hours to… More